Skip to main content
Lavipharm S.A. logo

Lavipharm S.A. — Investor Relations & Filings

Ticker · LAVI ISIN · GRS246003008 LEI · 213800USC69CRPRGWJ15 AT Manufacturing
Open in API
Filings indexed 42 across all filing types
Latest filing 2026-04-27 Investor Presentation
Country GR Greece
Listing AT LAVI

About Lavipharm S.A.

https://lavipharm.com/

Lavipharm S.A. is an integrated healthcare company engaged in the research, development, manufacturing, marketing, and distribution of pharmaceutical products. Established in 1911, the company offers a diverse portfolio that includes prescription (Rx) and over-the-counter (OTC) medicines, as well as food supplements. A key area of innovation for the company is its development of transdermal drug delivery systems. Lavipharm focuses on providing treatment options across several major therapeutic areas, including cardiology, neurology (Central Nervous System), urology, oncology, and chronic pain management.

Recent filings

Filing Released Lang Actions
ΕΝΗΜΕΡΩΣΗ ΑΝΑΛΥΤΩΝ
Investor Presentation Classification · 85% confidence The document is styled as a transcript/summary of an annual analyst update presentation by Lavipharm’s CFO and Deputy CEO to institutional investors, containing detailed financial metrics, strategic outlook, and market positioning. It is not a regulatory form or simple earnings release but a full investor presentation of results and strategy. This matches the “Investor Presentation (IP)” category.
2026-04-27 Greek (modern)
ANALYST BRIEFING
Investor Presentation Classification · 90% confidence The document is a corporate financial press release summarizing Lavipharm’s Annual Analyst Update Presentation to institutional investors. It provides detailed financial metrics, strategic commentary, and forward-looking initiatives—typical of a presentation aimed at investors rather than a simple earnings release or regulatory announcement. It does not merely announce or attach a report but conveys the content of the presentation itself. Therefore, it aligns with the “Investor Presentation” category (IP).
2026-04-27 English
Οικονομική έκθεση LAVIPHARM Α.Ε. (2025,Ετήσιος ισολογισμός,Ενοποιημένη)-iXBRL
Annual Report (ESEF) Classification · 100% confidence FY 2025
2026-04-23 Greek (modern)
Financial report LAVIPHARM S.A. (2025,Annual report,Consolidated)-iXBRL
Annual Report (ESEF) Classification · 100% confidence FY 2025
2026-04-23 English
Aνακοίνωση Επιχειρηματικών Εξελίξεων
M&A Activity Classification · 85% confidence The document is a corporate announcement by Lavipharm regarding its agreement to acquire prescription transdermal pharmaceutical product rights (DUROGESIC®) and associated trademarks from Janssen Global Services. It details the terms of the asset acquisition, purchase price, funding structure, and expected business impact. This is a merger and acquisition–type transaction announcement rather than a financing-only update or regulatory filing. Therefore, it fits the M&A Activity category (Code: TAR).
2026-04-09 Greek (modern)
Statement for Athens Stock Exchange
M&A Activity Classification · 88% confidence The document is a corporate announcement detailing the acquisition of rights and licenses for a prescription pain medication patch by Lavipharm, including transaction terms, consideration, financing, conditions, and strategic impact. This is clearly related to a merger or acquisition activity rather than a simple financing update or routine report. Therefore it falls under the “M&A Activity” category (Code: TAR).
2026-04-09 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.